Innate Pharma in-licenses OREGA biotech's first-in-class anti-CD39 checkpoint inhibitor program
Number of shares and voting rights of Innate Pharma as at January 6, 2016
Innate Pharma announces its financial calendar for 2016
Full-year report on Innate Pharma's liquidity contract with Gilbert Dupont
Upcoming investor conferences
Fourth clinical trial opened with monalizumab (IPH2201)
Number of shares and voting rights of Innate Pharma as at December 7, 2015
First patient dosed in Phase I trial of IPH4102
New combination trial with lirilumab in hemato-oncology
Third Quarter 2015 Report
